Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What's All the Fuss About

<< Previous

Bullboard Posts

Next >>

Comment by RalphRalphon Feb 17, 2021 6:18pm

240 Views

Post# 32591341

RE:What's All the Fuss About

The fuss is about 20%+ dilution for the second time in 9 months.

crow27 wrote: We needed this cash desperately and now we have all kinds of cash to complete Phase 3 on our own. 2 weeks ago this would have been done @ $3.00.
Full steam ahead with a pocket full of cash. If it drops and i mean if, then just buy more.
It's what the money will be used for is what counts and there could be nothing more important than phase 3. The markets know this.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?